On 10 March 2025, the Scottish Medicines Consortium (SMC) approved Talazoparib (brand name Talzenna®), in combination with enzalutamide, for use by NHS Scotland.  The treatment option is focused on men with metastatic castration-resistant prostate cancer (mCRPC) for whom chemotherapy is not clinically indicated.

The approval marks an important step forward in giving patients more options – especially those who cannot or do not want to undergo chemotherapy.

A link to a news article about the announcement:  News Link
A link to the SMC news release can be found here:  SMC link